Affiliation:
1. Department of Hematology, West China Hospital, Sichuan University, Chengdu
Abstract
Abstract
Objectives
Infection is one of the leading causes of death in hematology patients. Metagenomic next-generation sequencing (mNGS) has been applied to diagnose infection. This meta-analysis will focus on systematically assessing the diagnostic value of mNGS for infection in hematology patients.
Methods
We searched for studies that assessed the efficacy of mNGS for the diagnosis of infection in hematology patients published in Embase, PubMed, Cochrane Library, Web of Science, and China National Knowledge Infrastructure from inception to December 31, 2022. The pooled sensitivity and specificity were estimate and subgroup analysis was performed.
Results
The pooled sensitivity and specificity were 89.6% (95%CI: 88–91%) and 56% (95%CI: 44–69%), respectively. The pooled positive likelihood ratio and negative likelihood ratio were 2.10 (95%CI: 1.48–3.30) and 0.22 (95%CI: 0.15–0.32), respectively. And diagnostic odds ratio was 10.29 (95%CI: 4.61–19.72). The SROC (summary receiver operating characteristic) curve revealed an AUC (area under curve) of 0.88 (95%CI: 0.85–0.90). The method of sample selection and the research type/gold standard may be sources of heterogeneity in sensitivity and specificity, respectively.
Conclusion
mNGS has shown good diagnostic efficacy for infection in hematology patients, but it’s important to choose suitable samples for mNGS according to infection types.
Publisher
Research Square Platform LLC
Reference37 articles.
1. Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management;Crawford J;Cancer,2004
2. Inappropriate Empirical Antibiotic Treatment in High-risk Neutropenic Patients With Bacteremia in the Era of Multidrug Resistance;Martinez-Nadal G;Clin Infect Dis,2020
3. [Epidemiology of febrile neutropenia in patients with hematological disease-a prospective multicentre survey in China];Yan CH;Zhonghua Xue Ye Xue Za Zhi,2016
4. Prognostic Factors for Mortality among Day + 100 Survivors after Allogeneic Hematopoietic Cell Transplantation;Patel SS;Biol Blood Marrow Transplant,2018
5. Short versus extended treatment with a carbapenem in patients with high-risk fever of unknown origin during neutropenia: a non-inferiority, open-label, multicentre, randomised trial;Jonge NA;Lancet Haematol,2022